publication date: Dec. 19, 2010

In this issue: 

New drug approvals point to greater role of randomization in cancer clinical trials. European standards will demand more rigor.

Randomized trials discovered roles for newly approved Nexavar and Sutent.

NCI plans to expand CTSU management of clinical trials.

Download (PDF 1.3MB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.